SI21372A - Novi fibroblastni rastni faktorji - Google Patents

Novi fibroblastni rastni faktorji Download PDF

Info

Publication number
SI21372A
SI21372A SI200120066A SI200120066A SI21372A SI 21372 A SI21372 A SI 21372A SI 200120066 A SI200120066 A SI 200120066A SI 200120066 A SI200120066 A SI 200120066A SI 21372 A SI21372 A SI 21372A
Authority
SI
Slovenia
Prior art keywords
fgf
polypeptide
amino acid
nucleotide sequence
human
Prior art date
Application number
SI200120066A
Other languages
English (en)
Slovenian (sl)
Inventor
Peter W. Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SI21372A publication Critical patent/SI21372A/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200120066A 2000-12-08 2001-12-10 Novi fibroblastni rastni faktorji SI21372A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
SI21372A true SI21372A (sl) 2004-06-30

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200120066A SI21372A (sl) 2000-12-08 2001-12-10 Novi fibroblastni rastni faktorji

Country Status (21)

Country Link
US (2) US20020151496A1 (ru)
EP (1) EP1389237A2 (ru)
JP (1) JP2005506275A (ru)
KR (1) KR20040052442A (ru)
CN (1) CN1518597A (ru)
AU (1) AU2603402A (ru)
BG (1) BG107888A (ru)
BR (1) BR0116507A (ru)
CA (1) CA2431374A1 (ru)
CZ (1) CZ20031570A3 (ru)
EE (1) EE200300269A (ru)
HU (1) HUP0400657A1 (ru)
IL (1) IL156259A0 (ru)
MX (1) MXPA03005142A (ru)
NO (1) NO20032573L (ru)
PL (1) PL366158A1 (ru)
RU (1) RU2329058C2 (ru)
SI (1) SI21372A (ru)
SK (1) SK7012003A3 (ru)
WO (1) WO2002046424A2 (ru)
ZA (1) ZA200305236B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
CA2468610A1 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP2335738A1 (en) * 2003-04-01 2011-06-22 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell or target cell-based treatment of wound healing
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
PT2726511T (pt) 2011-07-01 2019-10-14 Ngm Biopharmaceuticals Inc Composições, usos e métodos para o tratamento de distúrbios e doenças metabólicas
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
BR112016009099A2 (pt) 2013-10-28 2017-09-19 Ngm Biopharmaceuticals Inc Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
KR102489475B1 (ko) 2014-01-24 2023-01-20 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 그의 사용 방법
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
ES2335386T3 (es) * 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
AU2001271811B2 (en) * 2000-07-03 2006-07-20 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
IL156259A0 (en) 2004-01-04
WO2002046424A2 (en) 2002-06-13
NO20032573L (no) 2003-07-22
AU2002226034A2 (en) 2002-06-18
BR0116507A (pt) 2004-01-06
CZ20031570A3 (cs) 2004-01-14
RU2329058C2 (ru) 2008-07-20
US20080057076A1 (en) 2008-03-06
ZA200305236B (en) 2005-06-29
SK7012003A3 (en) 2004-04-06
BG107888A (bg) 2004-08-31
AU2603402A (en) 2002-06-18
US20020151496A1 (en) 2002-10-17
RU2003119657A (ru) 2005-02-27
EE200300269A (et) 2003-10-15
EP1389237A2 (en) 2004-02-18
HUP0400657A1 (en) 2006-04-28
PL366158A1 (en) 2005-01-24
NO20032573D0 (no) 2003-06-06
WO2002046424A3 (en) 2003-11-27
JP2005506275A (ja) 2005-03-03
CN1518597A (zh) 2004-08-04
CA2431374A1 (en) 2002-06-13
KR20040052442A (ko) 2004-06-23
MXPA03005142A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
US6004937A (en) Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US8986690B2 (en) Modulation of activity of neurotrophins
EP1071772A2 (en) Fizz proteins
CA2343927A1 (en) Artemin, a novel neurotrophic factor
US20160152677A1 (en) Single domain tdf-related compounds and analogs thereof
Heller et al. Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development
AU735794B2 (en) Don-1 gene and polypeptides and uses therefor
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
AU2002226034B2 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
AU2002226034A1 (en) Fibroblast growth factors
WO1998017798A1 (en) Placental-derived prostate growth factors
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
Buj-Bello Neurotrophic actions of GDNF and neurturin in the developing avian nervous system and cloning and expression of their receptors
AU2016213791A1 (en) Single domain TDF-related compounds and analogs thereof

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20090717